Reviewer's report

Title: Safety, Pharmacokinetics and Pharmacodynamics of Remogliflozin Etabonate, a Novel SGLT2 Inhibitor, and Metformin when Co-administered in Subjects with Type 2 Diabetes Mellitus

Version: 4 Date: 6 February 2013

Reviewer: Yutaka Seino

Reviewer's report:

The manuscript entitled "Safety, Pharmacokinetics and Pharmacodynamics of Remogliflozin Etabonate, a Novel SGLT2 Inhibitor, and Metformin when Co-administered in Subjects with Type 2 DM" by Hussey et al is now revised substantially. However, the authors still need to address the issue #1, which I raised in the previous communication (i.e. definition of nephrotic proteinuria). The authors should cite appropriate references to validate their cut-off value, >2.5g/gCre.

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: Yes, but I do not feel adequately qualified to assess the statistics.

Declaration of competing interests:

I declare that I have no competing interests